Drug Discovery Services Market - Global Forecast to 2030
商品番号 : SMB-11069
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年3月 |
| ページ数 | 451 |
| 図表数 | 641 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global drug discovery services market is anticipated to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025, with a significant CAGR of 10.7%.
世界の創薬サービス市場は、2025年の163.6億米ドルから2030年には272.3億米ドルに達し、年平均成長率10.7%で成長すると予想されています。
The market is growing strongly at a considerable CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on the rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players are likely to witness healthy growth opportunities due to the technological advancement, new drug discovery techniques, patent expiry, and rising demand for specialized testing services among end users.
製薬会社やバイオ製薬会社の研究開発投資の増加により、市場は相当なCAGRで力強く成長しています。研究開発のパイプラインが拡大するにつれ、希少疾患や希少疾病用医薬品に関する研究イニシアチブに加えて、分析試験のアウトソーシングの要件も高まると見込まれています。さらに、社内での医薬品開発にかかる高コストもこの傾向に寄与しています。業界関係者は、技術の進歩、新薬発見技術、特許の満了、エンドユーザーの間での専門的な試験サービスに対する需要の高まりにより、健全な成長の機会を目の当たりにする可能性があります。
“Chemistry services dominated the type segment”
Based on type, the drug discovery services market is divided into chemistry services, and biology services. The chemistry services segment is further divided into synthetic chemistry services, analytical chemistry services, other chemistry services. The development of technologies like combinatorial chemistry and structure-based drug design has contributed to the growth of chemistry services. Chemistry’s extensive use in drug discovery particularly for lead molecule identification, lead modification or optimization, scale-up of the optimized lead for further drug development processes, and efficacy testing, has contributed to the growing demand for the segment.
“The hit-to-lead identification dominated the process segment”
Based on process, the drug discovery services market includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification services dominated the market. Growth in the hit-to-lead identification services market is predetermined due to its crucial place in drug discovery, being the maximum revenue-generating process. Many CROs offer these services to pharmaceutical companies. Moreover, key players are focusing on improving this critical step of drug discovery.
“The small molecules dominated the drug type segment”
Based on drug type, the drug discovery services market can be segmented into small molecules, and biologics. Small molecules would hold largest share in the market. The increasing growth of the small molecules can be attributed to several factors such as ease of working with, low costs, and increasing startup and new entrants focusing on small-molecule drug development. Small molecules can also easily enter the cells thanks to their low molecular weights. They may act on other molecules and kill cancer cells. As such, small molecules or small-molecule inhibitors are used extensively for many targeted therapies.
“Cardiovascular diseases segment is anticipated to grow at a great pace”
The therapeutic area segment is divided into oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women’s health, and other therapeutic areas. The market for cardiovascular diseases is dominated due to high prevalence of cardiovascular diseases, rising geriatric population, and increasing partnerships between CROs and pharmaceutical & biotechnology companies. The integration of genetic and personalized medicine innovations will also support the growth of cardiovascular disease therapeutic discovery and development.
“Pharmaceutical & Biotechnology Companies dominated the segment”
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic institutes, and other end users. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the drug discovery services market is due to the growing R&D expenditure for new molecules development, the increasing outsourcing of clinical services by these companies, and a strong pipeline of biotechnology companies to increase profit margins and reduce the time of drug development.
“US to grow at the highest CAGR for North America drug discovery services market”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the drug discovery services market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of key players. The country’s focus on R&D expenditure, and rapid growth in the biosimilar and biologics markets further boosts its leadership in the market. European drug discovery services market is experiencing steady growth, supported by demographic changes, the growing prevalence of diseases, and investments in R&D.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the drug discovery services market.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 55%, Tier 2 – 25%, and Tier 3 – 20%
- By Designation: Directors – 45%, Managers – 30%, and Others – 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Thermo Fisher Scientific Inc. (US), Labcorp (US), Eurofins Scientific (Germany), Charles River Laboratories (US), WuXi AppTec (China), Pharmaron (China), Evotec (Germany), Syngene International Limited (India), Curia Global, Inc. (US), Aragen Life Sciences Ltd. (India), Jubilant Pharmova Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Frontage Holdings Corporation (US), GenScript (US), Sygnature Discovery (UK), and Piramal Enterprises Ltd. (India) are some of the key players in the drug discovery services market.
Research Coverage:
Drug discovery services market report is segmented based on process (target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation), by type [(chemistry services (synthetic chemistry services, analytical chemistry services, other chemistry services), and biology services (in vitro profiling services, toxicology services, and other biology services)], by drug type (small molecules, and biologics), by therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women’s health, and other therapeutic areas), by end user (pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the drug discovery services and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, Increasing demand for outsourcing analytical testing services, Initiatives for research on rare diseases and orphan drugs, High cost of in-house drug development), restraints (Stringent regulations governing drug discovery and animal usages), opportunities (Growth in drugs and biologics market, Rising demand for specialized testing services among end users, Patent Expiry, High growth prospect in emerging markets) and Challenges (Economic uncertainties worldwide) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies in drug discovery services, research and development activities, and new service launches in the drug discovery services market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi AppTec (China), and Pharmaron (China), and Labcorp (US), among others.
Table of Contents
1 INTRODUCTION 41
1.1 STUDY OBJECTIVES 41
1.2 MARKET DEFINITION 41
1.3 STUDY SCOPE 42
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 42
1.3.2 INCLUSIONS AND EXCLUSIONS 43
1.3.3 YEARS CONSIDERED 44
1.4 CURRENCY CONSIDERED 44
1.5 STAKEHOLDERS 44
1.6 SUMMARY OF CHANGES 45
2 RESEARCH METHODOLOGY 46
2.1 RESEARCH DATA 46
2.1.1 SECONDARY DATA 47
2.1.1.1 Objectives of secondary research 47
2.1.2 PRIMARY DATA 47
2.1.2.1 Objectives of primary research 48
2.2 MARKET SIZE ESTIMATION 49
2.2.1 GLOBAL MARKET ESTIMATION 49
2.2.2 SEGMENTAL MARKET ESTIMATION 52
2.3 GROWTH RATE PROJECTIONS 53
2.4 DATA TRIANGULATION 55
2.5 RESEARCH ASSUMPTIONS 56
2.6 RESEARCH LIMITATIONS 57
2.7 RISK ANALYSIS 57
3 EXECUTIVE SUMMARY 58
4 PREMIUM INSIGHTS 63
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW 63
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET,
BY DRUG TYPE AND COUNTRY, 2024 64
4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 65
4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
5.2.1 DRIVERS 67
5.2.1.1 Booming research & development expenditure in
pharma-biotech sector 67
5.2.1.2 Growing pipeline of pharmaceutical and biopharmaceutical companies 68
5.2.1.3 Rising research on rare diseases and orphan drugs 69
5.2.1.4 Increasing reliance on outsourcing due to costly in-house drug development 70
5.2.2 RESTRAINTS 71
5.2.2.1 Stringent regulations 71
5.2.3 OPPORTUNITIES 72
5.2.3.1 Technological advancements and new drug discovery techniques 72
5.2.3.2 Rising demand for specialized testing services 73
5.2.3.3 Patent expiry of key biologics 73
5.2.3.4 High growth prospects in emerging markets 75
5.2.4 CHALLENGES 75
5.2.4.1 Economic uncertainties worldwide 75
5.2.5 MARKET TRENDS 76
5.2.5.1 Adoption of AI in drug discovery 76
5.2.5.2 Increased outsourcing in emerging economies 77
5.2.5.3 Consolidation of contract research organizations 78
5.2.5.4 Integrated end-to-end R&D service offerings 79
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
5.4 PRICING ANALYSIS 80
5.4.1 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE 81
5.4.2 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION 82
5.5 SUPPLY CHAIN ANALYSIS 83
5.6 VALUE CHAIN ANALYSIS 84
5.7 ECOSYSTEM ANALYSIS 86
5.8 INVESTMENT AND FUNDING SCENARIO 89
5.9 TECHNOLOGY ANALYSIS 91
5.9.1 KEY TECHNOLOGIES 91
5.9.1.1 High-throughput screening 91
5.9.1.2 CRISPR gene editing 92
5.9.1.3 Structure-based drug design/Computer-aided drug design 92
5.9.2 COMPLEMENTARY TECHNOLOGIES 93
5.9.2.1 Automated liquid handling 93
5.9.2.2 In silico modeling 93
5.9.2.3 Patient-derived xenografts and organoids 93
5.9.3 ADJACENT TECHNOLOGIES 94
5.9.3.1 Nanotechnology 94
5.9.3.2 Synthetic biology 94
5.9.3.3 Organ-on-a-chip technology 95
5.10 PATENT ANALYSIS 95
5.11 KEY CONFERENCES AND EVENTS, 2025–2026 98
5.12 REGULATORY LANDSCAPE 99
5.12.1 REGULATORY FRAMEWORK 99
5.12.1.1 North America 99
5.12.1.1.1 US 99
5.12.1.1.2 Canada 100
5.12.1.2 Europe 100
5.12.1.2.1 UK 100
5.12.1.3 Asia Pacific 101
5.12.1.3.1 China 101
5.12.1.3.2 Japan 101
5.12.1.3.3 India 102
5.12.1.3.4 South Korea 102
5.12.1.3.5 Australia 102
5.12.1.3.6 Rest of Asia Pacific 103
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
5.13 PORTER’S FIVE FORCES ANALYSIS 105
5.13.1 BARGAINING POWER OF SUPPLIERS 107
5.13.2 BARGAINING POWER OF BUYERS 107
5.13.3 THREAT OF NEW ENTRANTS 107
5.13.4 THREAT OF SUBSTITUTES 107
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 107
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 108
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 108
5.14.2 KEY BUYING CRITERIA, BY END USER 109
5.15 IMPACT OF AI ON DRUG DISCOVERY SERVICES MARKET 110
5.15.1 INTRODUCTION 110
5.15.2 MARKET POTENTIAL OF AI IN DRUG DISCOVERY SERVICES 110
5.15.3 AI USE CASES 111
5.15.4 FUTURE OF GENERATIVE AI IN DRUG DISCOVERY SERVICES MARKET 112
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS 113
6.1 INTRODUCTION 114
6.2 TARGET SELECTION 115
6.2.1 INCREASING FOCUS ON IDENTIFYING POTENTIAL DRUG TARGETS TO BOLSTER GROWTH 115
6.3 TARGET VALIDATION 118
6.3.1 INCREASING EMPHASIS ON AVOIDING LATE-STAGE FAILURE TO PROMOTE GROWTH 118
6.4 HIT-TO-LEAD IDENTIFICATION 122
6.4.1 RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET 122
6.5 LEAD OPTIMIZATION 125
6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS IN CLINICAL TRIALS TO STIMULATE GROWTH 125
6.6 CANDIDATE VALIDATION 128
6.6.1 GROWING ATTENTION ON POTENCY AND SPECIFICITY OF DRUGS TO BOOST MARKET 128
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE 132
7.1 INTRODUCTION 133
7.2 CHEMISTRY SERVICES 133
7.2.1 SYNTHETIC CHEMISTRY SERVICES 137
7.2.1.1 Increasing reliance on novel and efficient synthetic routes to augment growth 137
7.2.2 ANALYTICAL CHEMISTRY SERVICES 140
7.2.2.1 Rising demand for high-quality, safe, and effective drugs to support growth 140
7.2.3 OTHER CHEMISTRY SERVICES 143
7.3 BIOLOGY SERVICES 146
7.3.1 IN VITRO PROFILING SERVICES 150
7.3.1.1 Need for higher project productivity to speed up growth 150
7.3.2 TOXICOLOGY SERVICES 153
7.3.2.1 Growing emphasis on assessing safety profiles of new drug candidates to propel market 153
7.3.3 OTHER BIOLOGY SERVICES 156
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE 159
8.1 INTRODUCTION 160
8.2 SMALL MOLECULES 160
8.2.1 INCREASING FOCUS ON OPTIMIZING SMALL-MOLECULE LEADS TO AMPLIFY GROWTH 160
8.3 BIOLOGICS 164
8.3.1 GROWING ADVANCEMENTS IN BIOTECHNOLOGY TO BOOST MARKET 164
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA 168
9.1 INTRODUCTION 169
9.2 ONCOLOGY 170
9.2.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET 170
9.3 INFECTIOUS DISEASES 174
9.3.1 RISING EPIDEMIC OUTBREAKS TO ASSIST GROWTH 174
9.4 CARDIOVASCULAR DISEASES 177
9.4.1 HIGH MORTALITY RATES TO SPUR GROWTH 177
9.5 NEUROLOGICAL DISEASES 181
9.5.1 INCREASING RESEARCH & DEVELOPMENT INVESTMENTS FOR NEUROLOGICAL DISORDERS TO FAVOR GROWTH 181
9.6 IMMUNOLOGICAL DISORDERS 185
9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET 185
9.7 ENDOCRINE & METABOLIC DISORDERS 188
9.7.1 BOOMING DIABETIC POPULATION TO AID GROWTH 188
9.8 RESPIRATORY DISORDERS 192
9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH 192
9.9 DIGESTIVE SYSTEM DISEASES 195
9.9.1 CHANGING LIFESTYLE AND DIETARY HABITS TO PROMOTE GROWTH 195
9.10 GENITOURINARY DISEASES & WOMEN’S HEALTH 198
9.10.1 RISING AWARENESS ABOUT EARLY DIAGNOSIS AND TREATMENT TO SUSTAIN GROWTH 198
9.11 OTHER THERAPEUTIC AREAS 200
10 DRUG DISCOVERY SERVICES MARKET, BY END USER 204
10.1 INTRODUCTION 205
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 205
10.2.1 TIER 1 COMPANIES 209
10.2.1.1 Rising research & development activities to sustain growth 209
10.2.2 TIER 2 COMPANIES 212
10.2.2.1 Growing focus on specific therapeutic areas to drive market 212
10.2.3 TIER 3 COMPANIES 215
10.2.3.1 Increasing specialized drug discovery projects to expedite growth 215
10.3 ACADEMIC INSTITUTES 218
10.3.1 INCREASING COLLABORATIONS AMONG MARKET PLAYERS TO CONTRIBUTE TO GROWTH 218
10.4 OTHER END USERS 221
11 DRUG DISCOVERY SERVICES MARKET, BY REGION 224
11.1 INTRODUCTION 225
11.2 NORTH AMERICA 225
11.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA 230
11.2.2 US 231
11.2.2.1 Global leadership in pharmaceutical and biopharmaceutical research to aid growth 231
11.2.3 CANADA 235
11.2.3.1 Increasing initiatives for commercializing drugs to stimulate growth 235
11.3 EUROPE 239
11.3.1 MACROECONOMIC OUTLOOK OF EUROPE 243
11.3.2 GERMANY 244
11.3.2.1 Rising dominance of contract research organizations to encourage growth 244
11.3.3 UK 248
11.3.3.1 Increasing government-private sector collaborations to boost market 248
11.3.4 FRANCE 251
11.3.4.1 Growing number of oncology research projects to propel market 251
11.3.5 ITALY 255
11.3.5.1 High number of clinical trials and low drug approval time to promote growth 255
11.3.6 SPAIN 259
11.3.6.1 Rising elderly population to intensify growth 259
11.3.7 REST OF EUROPE 263
11.4 ASIA PACIFIC 267
11.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC 272
11.4.2 CHINA 273
11.4.2.1 Booming pharmaceutical industry to sustain growth 273
11.4.3 JAPAN 277
11.4.3.1 Increasing geriatric population to support growth 277
11.4.4 INDIA 281
11.4.4.1 Growing foreign direct investments to drive market 281
11.4.5 SOUTH KOREA 285
11.4.5.1 Favorable government support to accelerate growth 285
11.4.6 AUSTRALIA 289
11.4.6.1 Rising number of clinical trials to foster growth 289
11.4.7 REST OF ASIA PACIFIC 293
11.5 LATIN AMERICA 296
11.5.1 MACROECONOMIC OUTLOOK OF LATIN AMERICA 300
11.5.2 BRAZIL 301
11.5.2.1 Reduced timeline for drug approvals to favor growth 301
11.5.3 MEXICO 304
11.5.3.1 Favorable government policies to intensify growth 304
11.5.4 REST OF LATIN AMERICA 307
11.6 MIDDLE EAST 311
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 315
11.6.2 GCC COUNTRIES 316
11.6.2.1 Saudi Arabia 319
11.6.2.1.1 Booming healthcare expenditure to contribute to growth 319
11.6.2.2 UAE 323
11.6.2.2.1 Rising government initiatives for advanced healthcare to amplify growth 323
11.6.2.3 Other GCC Countries 327
11.6.3 REST OF MIDDLE EAST 331
11.7 AFRICA 335
11.7.1 RISING BURDEN OF CANCER AND CHRONIC DISEASES TO FACILITATE GROWTH 335
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 339
12 COMPETITIVE LANDSCAPE 340
12.1 INTRODUCTION 340
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 340
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET 341
12.3 REVENUE ANALYSIS, 2020−2024 344
12.4 MARKET SHARE ANALYSIS, 2024 345
12.5 COMPANY VALUATION AND FINANCIAL METRICS 348
12.6 BRAND/SERVICE COMPARISON 349
12.6.1 THERMO FISHER SCIENTIFIC INC. (US) 350
12.6.2 CHARLES RIVER LABORATORIES (US) 350
12.6.3 LABCORP (US) 350
12.6.4 WUXI APPTEC (CHINA) 350
12.6.5 PHARMARON (CHINA) 350
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 351
12.7.1 STARS 351
12.7.2 EMERGING LEADERS 351
12.7.3 PERVASIVE PLAYERS 351
12.7.4 PARTICIPANTS 351
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 353
12.7.5.1 Company footprint 353
12.7.5.2 Region footprint 354
12.7.5.3 Process footprint 355
12.7.5.4 Type footprint 356
12.7.5.5 Therapeutic area footprint 357
12.7.5.6 Drug type footprint 358
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 359
12.8.1 PROGRESSIVE COMPANIES 359
12.8.2 RESPONSIVE COMPANIES 359
12.8.3 DYNAMIC COMPANIES 359
12.8.4 STARTING BLOCKS 359
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES 361
12.8.5.1 Detailed list of key startups/SMEs 361
12.8.5.2 Competitive benchmarking of key startups/SMEs 362
12.9 COMPETITIVE SCENARIO 362
12.9.1 SERVICE LAUNCHES 362
12.9.2 DEALS 364
12.9.3 EXPANSIONS 365
12.9.4 OTHER DEVELOPMENTS 366
13 COMPANY PROFILES 367
13.1 KEY PLAYERS 367
13.1.1 THERMO FISHER SCIENTIFIC INC. 367
13.1.1.1 Business overview 367
13.1.1.2 Services offered 369
13.1.1.3 Recent developments 369
13.1.1.3.1 Service launches 369
13.1.1.3.2 Deals 370
13.1.1.3.3 Expansions 370
13.1.1.4 MnM view 371
13.1.1.4.1 Key strengths 371
13.1.1.4.2 Strategic choices 371
13.1.1.4.3 Weaknesses and competitive threats 371
13.1.2 CHARLES RIVER LABORATORIES 372
13.1.2.1 Business overview 372
13.1.2.2 Services offered 374
13.1.2.3 Recent developments 375
13.1.2.3.1 Service launches 375
13.1.2.3.2 Deals 375
13.1.2.4 MnM view 377
13.1.2.4.1 Key strengths 377
13.1.2.4.2 Strategic choices 377
13.1.2.4.3 Weaknesses and competitive threats 377
13.1.3 WUXI APPTEC 378
13.1.3.1 Business overview 378
13.1.3.2 Services offered 380
13.1.3.3 Recent developments 381
13.1.3.3.1 Expansions 381
13.1.3.4 MnM view 382
13.1.3.4.1 Key strengths 382
13.1.3.4.2 Strategic choices 382
13.1.3.4.3 Weaknesses and competitive threats 382
13.1.4 PHARMARON 383
13.1.4.1 Business overview 383
13.1.4.2 Services offered 384
13.1.4.2.1 Deals 387
13.1.4.3 MnM view 388
13.1.4.3.1 Key strengths 388
13.1.4.3.2 Strategic choices 388
13.1.4.3.3 Weaknesses and competitive threats 388
13.1.5 LABCORP 389
13.1.5.1 Business overview 389
13.1.5.2 Services offered 391
13.1.5.3 Recent developments 391
13.1.5.3.1 Deals 391
13.1.5.3.2 Expansions 392
13.1.5.4 MnM view 392
13.1.5.4.1 Key strengths 392
13.1.5.4.2 Strategic choices 393
13.1.5.4.3 Weaknesses and competitive threats 393
13.1.6 EVOTEC 394
13.1.6.1 Business overview 394
13.1.6.2 Services offered 395
13.1.6.3 Recent developments 396
13.1.6.3.1 Deals 396
13.1.6.3.2 Expansions 398
13.1.6.3.3 Other developments 398
13.1.7 SYNGENE INTERNATIONAL LIMITED 399
13.1.7.1 Business overview 399
13.1.7.2 Services offered 400
13.1.7.3 Recent developments 401
13.1.7.3.1 Deals 401
13.1.7.3.2 Expansions 401
13.1.8 EUROFINS SCIENTIFIC 402
13.1.8.1 Business overview 402
13.1.8.2 Services offered 403
13.1.8.3 Recent developments 404
13.1.8.3.1 Service launches 404
13.1.8.3.2 Deals 405
13.1.8.3.3 Expansions 405
13.1.9 JUBILANT PHARMOVA LIMITED 406
13.1.9.1 Business overview 406
13.1.9.2 Services offered 407
13.1.9.3 Recent developments 408
13.1.9.3.1 Deals 408
13.1.9.3.2 Expansions 409
13.1.10 GENSCRIPT 410
13.1.10.1 Business overview 410
13.1.10.2 Services offered 411
13.1.10.3 Recent developments 412
13.1.10.3.1 Service launches 412
13.1.10.3.2 Deals 412
13.1.11 FRONTAGE HOLDINGS CORPORATION 413
13.1.11.1 Business overview 413
13.1.11.2 Services offered 415
13.1.11.3 Recent developments 416
13.1.11.3.1 Service launches 416
13.1.11.3.2 Deals 416
13.1.11.3.3 Expansions 417
13.1.12 PIRAMAL ENTERPRISES LTD. 418
13.1.12.1 Business overview 418
13.1.12.2 Services offered 419
13.1.12.3 Recent developments 420
13.1.12.3.1 Expansions 420
13.1.13 AURIGENE PHARMACEUTICAL SERVICES LTD. 421
13.1.13.1 Business overview 421
13.1.13.2 Services offered 422
13.1.13.3 Recent developments 423
13.1.13.3.1 Service launches 423
13.1.13.3.2 Deals 423
13.1.13.3.3 Expansions 424
13.1.14 CURIA GLOBAL, INC. 425
13.1.14.1 Business overview 425
13.1.14.2 Services offered 425
13.1.14.3 Recent developments 426
13.1.14.3.1 Service launches 426
13.1.14.3.2 Deals 427
13.1.14.3.3 Other developments 427
13.1.15 SHANGHAI MEDICILON INC. 428
13.1.15.1 Business overview 428
13.1.15.2 Services offered 428
13.1.15.3 Recent developments 429
13.1.15.3.1 Deals 429
13.1.15.3.2 Expansions 429
13.1.16 SYGNATURE DISCOVERY 430
13.1.16.1 Business overview 430
13.1.16.2 Services offered 430
13.1.16.2.1 Deals 431
13.1.16.2.2 Expansions 432
13.2 OTHER PLAYERS 433
13.2.1 SELVITA 433
13.2.2 VIVA BIOTECH 434
13.2.3 TCG LIFESCIENCES PVT. LTD. 435
13.2.4 SHANGHAI CHEMPARTNER 436
13.2.5 DOMAINEX 437
13.2.6 NUVISAN GMBH 438
13.2.7 DALTON PHARMA SERVICES 439
13.2.8 ARAGEN LIFE SCIENCES LTD. 440
13.2.9 ONCODESIGN SERVICES 441
14 APPENDIX 442
14.1 DISCUSSION GUIDE 442
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 446
14.3 CUSTOMIZATION OPTIONS 448
14.4 RELATED REPORTS 449
14.5 AUTHOR DETAILS 450
LIST OF TABLES
TABLE 1 DRUG DISCOVERY SERVICES MARKET: INCLUSIONS AND EXCLUSIONS 43
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 54
TABLE 3 DRUG DISCOVERY SERVICES MARKET: RISK ANALYSIS 57
TABLE 4 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 67
TABLE 5 US: BIOLOGICS GOING OFF PATENT, 2025–2030 74
TABLE 6 DRUG DISCOVERY SERVICES MARKET: PROMINENT ACQUISITIONS, 2021–2024 78
TABLE 7 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES,
BY TYPE, 2024 (USD) 81
TABLE 8 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES,
BY REGION, 2024 (USD) 82
TABLE 9 DRUG DISCOVERY SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 88
TABLE 10 INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021−2025 89
TABLE 11 DRUG DISCOVERY SERVICES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021–2024 97
TABLE 12 DRUG DISCOVERY SERVICES MARKET: KEY CONFERENCES AND EVENTS,
2025–2026 98
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 103
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 104
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 104
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 105
TABLE 17 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 106
TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 108
TABLE 19 KEY BUYING CRITERIA, BY END USER 109
TABLE 20 KEY COMPANIES IMPLEMENTING AI 111
TABLE 21 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 114
TABLE 22 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 23 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 24 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION,
BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 25 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 26 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 27 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION,
BY REGION, 2023–2030 (USD MILLION) 117
TABLE 28 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 29 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION) 119
TABLE 30 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 31 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION,
BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 32 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION,
BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 33 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 34 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION,
BY REGION, 2023–2030 (USD MILLION) 121
TABLE 35 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 36 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION,
BY REGION, 2023–2030 (USD MILLION) 123
TABLE 37 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 38 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 39 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 40 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 41 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION) 124
TABLE 42 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 43 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION) 126
TABLE 44 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 45 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION,
BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 46 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION,
BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 47 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 48 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION,
BY REGION, 2023–2030 (USD MILLION) 127
TABLE 49 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 50 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION) 129
TABLE 51 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 52 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION,
BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 53 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 54 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 55 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION) 131
TABLE 56 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 57 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 133
TABLE 58 DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 134
TABLE 59 DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 134
TABLE 60 NORTH AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 61 EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 135
TABLE 62 ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 63 LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 64 MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 136
TABLE 65 GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 66 DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 137
TABLE 67 NORTH AMERICA: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 68 EUROPE: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 69 ASIA PACIFIC: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 70 LATIN AMERICA: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 71 MIDDLE EAST: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET,
BY REGION, 2023–2030 (USD MILLION) 139
TABLE 72 GCC COUNTRIES: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 73 DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 140
TABLE 74 NORTH AMERICA: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 75 EUROPE: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 76 ASIA PACIFIC: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 77 LATIN AMERICA: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 78 MIDDLE EAST: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET,
BY REGION, 2023–2030 (USD MILLION) 142
TABLE 79 GCC COUNTRIES: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 80 OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 143
TABLE 81 NORTH AMERICA: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKE,
BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 82 EUROPE: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 83 ASIA PACIFIC: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 84 LATIN AMERICA: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 85 MIDDLE EAST: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY REGION, 2023–2030 (USD MILLION) 145
TABLE 86 GCC COUNTRIES: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 87 DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 147
TABLE 88 DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 147
TABLE 89 NORTH AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 90 EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 91 ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 92 LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 93 MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 149
TABLE 94 GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 95 DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 150
TABLE 96 NORTH AMERICA: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 97 EUROPE: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 98 ASIA PACIFIC: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 99 LATIN AMERICA: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 100 MIDDLE EAST: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET,
BY REGION, 2023–2030 (USD MILLION) 152
TABLE 101 GCC COUNTRIES: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 102 DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 153
TABLE 103 NORTH AMERICA: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 104 EUROPE: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 154
TABLE 105 ASIA PACIFIC: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 106 LATIN AMERICA: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 107 MIDDLE EAST: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 108 GCC COUNTRIES: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 109 OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 156
TABLE 110 NORTH AMERICA: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 111 EUROPE: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 112 ASIA PACIFIC: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 113 LATIN AMERICA: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 114 MIDDLE EAST: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 158
TABLE 115 GCC COUNTRIES: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 116 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 160
TABLE 117 DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 161
TABLE 118 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 119 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 120 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 121 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 122 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES,
BY REGION, 2023–2030 (USD MILLION) 163
TABLE 123 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 124 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION,
2023–2030 (USD MILLION) 165
TABLE 125 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS,
BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 126 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 127 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS,
BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 128 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS,
BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 129 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 166
TABLE 130 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS,
BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 131 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 169
TABLE 132 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY, 2024 170
TABLE 133 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION,
2023–2030 (USD MILLION) 171
TABLE 134 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 135 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 136 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 137 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 138 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY,
BY REGION, 2023–2030 (USD MILLION) 173
TABLE 139 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 140 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 174
TABLE 141 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 142 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 143 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 144 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 145 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 146 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 147 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES, 2024 177
TABLE 148 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES,
BY REGION, 2023–2030 (USD MILLION) 178
TABLE 149 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 150 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 151 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 152 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 153 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 180
TABLE 154 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 155 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS, 2024 182
TABLE 156 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 182
TABLE 157 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 158 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 159 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 160 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 161 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 184
TABLE 162 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 163 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS, 2024 185
TABLE 164 DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 186
TABLE 165 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 166 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 167 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 168 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 169 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 187
TABLE 170 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 188
TABLE 171 DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 189
TABLE 172 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 173 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 174 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 175 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 176 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 191
TABLE 177 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 178 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS, 2024 192
TABLE 179 DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION) 193
TABLE 180 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 181 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 182 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 183 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 184 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION) 194
TABLE 185 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 195
TABLE 186 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES,
BY REGION, 2023–2030 (USD MILLION) 195
TABLE 187 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 188 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 189 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 190 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 191 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2023–2030 (USD MILLION) 197
TABLE 192 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 193 DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION) 198
TABLE 194 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 195 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 196 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 197 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 198 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION) 200
TABLE 199 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 200 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 201
TABLE 201 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 202 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 203 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 204 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 205 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 203
TABLE 206 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 207 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 205
TABLE 208 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 206
TABLE 209 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 206
TABLE 210 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 207
TABLE 211 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 207
TABLE 212 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 213 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 208
TABLE 214 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 215 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 209
TABLE 216 TOP REVENUE-GENERATING PHARMA COMPANIES, 2023 209
TABLE 217 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION,
2023–2030 (USD MILLION) 210
TABLE 218 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 210
TABLE 219 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 210
TABLE 220 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 221 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 222 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES,
BY REGION, 2023–2030 (USD MILLION) 211
TABLE 223 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 224 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION,
2023–2030 (USD MILLION) 212
TABLE 225 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 226 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 227 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 228 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 214
TABLE 229 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES,
BY REGION, 2023–2030 (USD MILLION) 214
TABLE 230 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 214
TABLE 231 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION,
2023–2030 (USD MILLION) 215
TABLE 232 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 233 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 216
TABLE 234 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 216
TABLE 235 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 217
TABLE 236 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES,
BY REGION, 2023–2030 (USD MILLION) 217
TABLE 237 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 217
TABLE 238 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 218
TABLE 239 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219
TABLE 240 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2023–2030 (USD MILLION) 219
TABLE 241 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219
TABLE 242 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 220
TABLE 243 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 220
TABLE 244 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 220
TABLE 245 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION,
2023–2030 (USD MILLION) 221
TABLE 246 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 221
TABLE 247 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 222
TABLE 248 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 222
TABLE 249 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 222
TABLE 250 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS,
BY REGION, 2023–2030 (USD MILLION) 223
TABLE 251 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 223
TABLE 252 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 225
TABLE 253 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 227
TABLE 254 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 227
TABLE 255 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 227
TABLE 256 NORTH AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 257 NORTH AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 228
TABLE 258 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 228
TABLE 259 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 229
TABLE 260 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 229
TABLE 261 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 230
TABLE 262 KEY MACROECONOMIC INDICATORS OF NORTH AMERICA 230
TABLE 263 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 232
TABLE 264 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 265 US: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 232
TABLE 266 US: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 233
TABLE 267 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 233
TABLE 268 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 234
TABLE 269 US: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 234
TABLE 270 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 271 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 236
TABLE 272 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 236
TABLE 273 CANADA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 236
TABLE 274 CANADA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 237
TABLE 275 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 237
TABLE 276 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 238
TABLE 277 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 238
TABLE 278 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 239
TABLE 279 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 240
TABLE 280 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 240
TABLE 281 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 240
TABLE 282 EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 241
TABLE 283 EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 241
TABLE 284 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 241
TABLE 285 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 242
TABLE 286 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 242
TABLE 287 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 243
TABLE 288 KEY MACROECONOMIC INDICATORS OF EUROPE 244
TABLE 289 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 245
TABLE 290 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 245
TABLE 291 GERMANY: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 245
TABLE 292 GERMANY: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 246
TABLE 293 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 246
TABLE 294 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 247
TABLE 295 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 247
TABLE 296 GERMANY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 248
TABLE 297 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 248
TABLE 298 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 249
TABLE 299 UK: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 249
TABLE 300 UK: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 249
TABLE 301 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 250
TABLE 302 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 250
TABLE 303 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 251
TABLE 304 UK: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 251
TABLE 305 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 252
TABLE 306 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 252
TABLE 307 FRANCE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 253
TABLE 308 FRANCE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 253
TABLE 309 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 253
TABLE 310 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 254
TABLE 311 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 254
TABLE 312 FRANCE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 255
TABLE 313 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 256
TABLE 314 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 256
TABLE 315 ITALY: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 256
TABLE 316 ITALY: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 257
TABLE 317 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 257
TABLE 318 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 258
TABLE 319 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 258
TABLE 320 ITALY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 321 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 260
TABLE 322 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 260
TABLE 323 SPAIN: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 260
TABLE 324 SPAIN: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 261
TABLE 325 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 261
TABLE 326 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 262
TABLE 327 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 262
TABLE 328 SPAIN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 263
TABLE 329 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 264
TABLE 330 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 264
TABLE 331 REST OF EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 332 REST OF EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 333 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 265
TABLE 334 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 266
TABLE 335 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 266
TABLE 336 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 267
TABLE 337 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 269
TABLE 338 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 269
TABLE 339 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 270
TABLE 340 ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 270
TABLE 341 ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 270
TABLE 342 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 271
TABLE 343 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 271
TABLE 344 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 272
TABLE 345 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 272
TABLE 346 KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC 273
TABLE 347 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 274
TABLE 348 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 274
TABLE 349 CHINA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 274
TABLE 350 CHINA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 275
TABLE 351 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 275
TABLE 352 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 276
TABLE 353 CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 276
TABLE 354 CHINA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 277
TABLE 355 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 278
TABLE 356 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 278
TABLE 357 JAPAN: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 278
TABLE 358 JAPAN: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 279
TABLE 359 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 279
TABLE 360 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 280
TABLE 361 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 280
TABLE 362 JAPAN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 281
TABLE 363 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 282
TABLE 364 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 282
TABLE 365 INDIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 282
TABLE 366 INDIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 283
TABLE 367 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 283
TABLE 368 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 284
TABLE 369 INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 284
TABLE 370 INDIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 285
TABLE 371 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 286
TABLE 372 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 286
TABLE 373 SOUTH KOREA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 286
TABLE 374 SOUTH KOREA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 287
TABLE 375 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 287
TABLE 376 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 288
TABLE 377 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 288
TABLE 378 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 289
TABLE 379 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 290
TABLE 380 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 290
TABLE 381 AUSTRALIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 290
TABLE 382 AUSTRALIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 291
TABLE 383 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 291
TABLE 384 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 292
TABLE 385 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 292
TABLE 386 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 293
TABLE 387 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 293
TABLE 388 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 294
TABLE 389 REST OF ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY TYPE, 2023–2030 (USD MILLION) 294
TABLE 390 REST OF ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 294
TABLE 391 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 295
TABLE 392 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 295
TABLE 393 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 296
TABLE 394 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE,
2023–2030 (USD MILLION) 296
TABLE 395 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 297
TABLE 396 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 297
TABLE 397 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 297
TABLE 398 LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 298
TABLE 399 LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 298
TABLE 400 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 298
TABLE 401 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 299
TABLE 402 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 299
TABLE 403 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 300
TABLE 404 KEY MACROECONOMIC INDICATORS OF LATIN AMERICA 300
TABLE 405 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 301
TABLE 406 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 301
TABLE 407 BRAZIL: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 302
TABLE 408 BRAZIL: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 302
TABLE 409 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 302
TABLE 410 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 303
TABLE 411 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 303
TABLE 412 BRAZIL: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 304
TABLE 413 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 304
TABLE 414 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 305
TABLE 415 MEXICO: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 305
TABLE 416 MEXICO: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 305
TABLE 417 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 306
TABLE 418 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 306
TABLE 419 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 307
TABLE 420 MEXICO: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 307
TABLE 421 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 308
TABLE 422 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 308
TABLE 423 REST OF LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY TYPE, 2023–2030 (USD MILLION) 308
TABLE 424 REST OF LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET,
BY TYPE, 2023–2030 (USD MILLION) 309
TABLE 425 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 309
TABLE 426 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 310
TABLE 427 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 310
TABLE 428 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE,
2023–2030 (USD MILLION) 311
TABLE 429 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 312
TABLE 430 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 312
TABLE 431 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 312
TABLE 432 MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 313
TABLE 433 MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 313
TABLE 434 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 313
TABLE 435 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 314
TABLE 436 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 314
TABLE 437 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 315
TABLE 438 KEY MACROECONOMIC INDICATORS OF MIDDLE EAST 315
TABLE 439 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 316
TABLE 440 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 316
TABLE 441 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 317
TABLE 442 GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY TYPE, 2023–2030 (USD MILLION) 317
TABLE 443 GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 317
TABLE 444 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 318
TABLE 445 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 318
TABLE 446 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 319
TABLE 447 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 319
TABLE 448 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 320
TABLE 449 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 320
TABLE 450 SAUDI ARABIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 320
TABLE 451 SAUDI ARABIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 321
TABLE 452 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 321
TABLE 453 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 322
TABLE 454 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 322
TABLE 455 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 323
TABLE 456 UAE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 324
TABLE 457 UAE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 324
TABLE 458 UAE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 324
TABLE 459 UAE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 325
TABLE 460 UAE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 325
TABLE 461 UAE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 326
TABLE 462 UAE: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 326
TABLE 463 UAE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 327
TABLE 464 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 328
TABLE 465 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 328
TABLE 466 OTHER GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY TYPE, 2023–2030 (USD MILLION) 328
TABLE 467 OTHER GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 329
TABLE 468 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 329
TABLE 469 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 330
TABLE 470 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 330
TABLE 471 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE,
2023–2030 (USD MILLION) 331
TABLE 472 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 332
TABLE 473 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 332
TABLE 474 REST OF MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET,
BY TYPE, 2023–2030 (USD MILLION) 332
TABLE 475 REST OF MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 333
TABLE 476 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 333
TABLE 477 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 334
TABLE 478 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 334
TABLE 479 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE,
2023–2030 (USD MILLION) 335
TABLE 480 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 336
TABLE 481 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 336
TABLE 482 AFRICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 336
TABLE 483 AFRICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 337
TABLE 484 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 337
TABLE 485 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 338
TABLE 486 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 338
TABLE 487 AFRICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 339
TABLE 488 KEY MACROECONOMIC INDICATORS OF AFRICA 339
TABLE 489 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2021−2024 341
TABLE 490 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION 346
TABLE 491 DRUG DISCOVERY SERVICES MARKET: REGION FOOTPRINT 354
TABLE 492 DRUG DISCOVERY SERVICES MARKET: PROCESS FOOTPRINT 355
TABLE 493 DRUG DISCOVERY SERVICES MARKET: TYPE FOOTPRINT 356
TABLE 494 DRUG DISCOVERY SERVICES MARKET: THERAPEUTIC AREA FOOTPRINT 357
TABLE 495 DRUG DISCOVERY SERVICES MARKET: DRUG TYPE FOOTPRINT 358
TABLE 496 DRUG DISCOVERY SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 361
TABLE 497 DRUG DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING
OF KEY STARTUPS/SMES 362
TABLE 498 DRUG DISCOVERY SERVICES MARKET: SERVICE LAUNCHES,
JANUARY 2021–JANUARY 2025 363
TABLE 499 DRUG DISCOVERY SERVICES MARKET: DEALS, JANUARY 2021–JANUARY 2025 364
TABLE 500 DRUG DISCOVERY SERVICES MARKET: EXPANSIONS,
JANUARY 2021–JANUARY 2025 365
TABLE 501 DRUG DISCOVERY SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 366
TABLE 502 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 367
TABLE 503 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 369
TABLE 504 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES,
JANUARY 2021–JANUARY 2025 369
TABLE 505 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2025 370
TABLE 506 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025 370
TABLE 507 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 372
TABLE 508 CHARLES RIVER LABORATORIES: SERVICES OFFERED 374
TABLE 509 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES,
JANUARY 2021–JANUARY 2025 375
TABLE 510 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–JANUARY 2025 375
TABLE 511 WUXI APPTEC: COMPANY OVERVIEW 378
TABLE 512 WUXI APPTEC: SERVICES OFFERED 380
TABLE 513 WUXI APPTEC: EXPANSIONS, JANUARY 2021–JANUARY 2025 381
TABLE 514 PHARMARON: COMPANY OVERVIEW 383
TABLE 515 PHARMARON: SERVICES OFFERED 384
TABLE 516 PHARMARON: DEALS, JANUARY 2021–JANUARY 2025 387
TABLE 517 LABCORP: COMPANY OVERVIEW 389
TABLE 518 LABCORP: SERVICES OFFERED 391
TABLE 519 LABCORP: DEALS, JANUARY 2021–JANUARY 2025 391
TABLE 520 LABCORP: EXPANSIONS, JANUARY 2021–JANUARY 2025 392
TABLE 521 EVOTEC: COMPANY OVERVIEW 394
TABLE 522 EVOTEC: SERVICES OFFERED 395
TABLE 523 EVOTEC: DEALS, JANUARY 2021–JANUARY 2025 396
TABLE 524 EVOTEC: EXPANSIONS, JANUARY 2021–JANUARY 2025 398
TABLE 525 EVOTEC: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 398
TABLE 526 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW 399
TABLE 527 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED 400
TABLE 528 SYNGENE INTERNATIONAL LIMITED: DEALS, JANUARY 2021–JANUARY 2025 401
TABLE 529 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2021–JANUARY 2025 401
TABLE 530 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 402
TABLE 531 EUROFINS SCIENTIFIC: SERVICES OFFERED 403
TABLE 532 EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 404
TABLE 533 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–JANUARY 2025 405
TABLE 534 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021–JANUARY 2025 405
TABLE 535 JUBILANT PHARMOVA LIMITED: COMPANY OVERVIEW 406
TABLE 536 JUBILANT PHARMOVA LIMITED: SERVICES OFFERED 407
TABLE 537 JUBILANT PHARMOVA LIMITED: DEALS, JANUARY 2021–JANUARY 2025 408
TABLE 538 JUBILANT PHARMOVA LIMITED: EXPANSIONS, JANUARY 2021–JANUARY 2025 409
TABLE 539 GENSCRIPT: COMPANY OVERVIEW 410
TABLE 540 GENSCRIPT: SERVICES OFFERED 411
TABLE 541 GENSCRIPT: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 412
TABLE 542 GENSCRIPT: DEALS, JANUARY 2021–JANUARY 2025 412
TABLE 543 FRONTAGE HOLDINGS CORPORATION: COMPANY OVERVIEW 413
TABLE 544 FRONTAGE HOLDINGS CORPORATION: SERVICES OFFERED 415
TABLE 545 FRONTAGE HOLDINGS CORPORATION: SERVICE LAUNCHES,
JANUARY 2021–JANUARY 2025 416
TABLE 546 FRONTAGE HOLDINGS CORPORATION: DEALS, JANUARY 2021–JANUARY 2025 416
TABLE 547 FRONTAGE HOLDINGS CORPORATION: EXPANSIONS,
JANUARY 2021–JANUARY 2025 417
TABLE 548 PIRAMAL ENTERPRISES LTD.: COMPANY OVERVIEW 418
TABLE 549 PIRAMAL ENTERPRISES LTD.: SERVICES OFFERED 419
TABLE 550 PIRAMAL ENTERPRISES LTD.: EXPANSIONS, JANUARY 2021–JANUARY 2025 420
TABLE 551 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW 421
TABLE 552 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED 422
TABLE 553 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 423
TABLE 554 AURIGENE PHARMACEUTICAL SERVICES LTD.: DEALS,
JANUARY 2021–JANUARY 2025 423
TABLE 555 AURIGENE PHARMACEUTICAL SERVICES LTD.: EXPANSIONS,
JANUARY 2021–JANUARY 2025 424
TABLE 556 CURIA GLOBAL, INC.: COMPANY OVERVIEW 425
TABLE 557 CURIA GLOBAL, INC.: SERVICES OFFERED 425
TABLE 558 CURIA GLOBAL, INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 426
TABLE 559 CURIA GLOBAL, INC.: DEALS, JANUARY 2021–JANUARY 2025 427
TABLE 560 CURIA GLOBAL, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 427
TABLE 561 SHANGHAI MEDICILON INC.: COMPANY OVERVIEW 428
TABLE 562 SHANGHAI MEDICILON INC.: SERVICES OFFERED 428
TABLE 563 SHANGHAI MEDICILON INC.: DEALS, JANUARY 2021–JANUARY 2025 429
TABLE 564 SHANGHAI MEDICILON INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025 429
TABLE 565 SYGNATURE DISCOVERY: COMPANY OVERVIEW 430
TABLE 566 SYGNATURE DISCOVERY: SERVICES OFFERED 430
TABLE 567 SYGNATURE DISCOVERY: DEALS, JANUARY 2021–JANUARY 2025 431
TABLE 568 SYGNATURE DISCOVERY: EXPANSIONS, JANUARY 2021–JANUARY 2025 432
TABLE 569 SELVITA: COMPANY OVERVIEW 433
TABLE 570 VIVA BIOTECH: COMPANY OVERVIEW 434
TABLE 571 TCG LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW 435
TABLE 572 SHANGHAI CHEMPARTNER: COMPANY OVERVIEW 436
TABLE 573 DOMAINEX: COMPANY OVERVIEW 437
TABLE 574 NUVISAN GMBH: COMPANY OVERVIEW 438
TABLE 575 DALTON PHARMA SERVICES: COMPANY OVERVIEW 439
TABLE 576 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW 440
TABLE 577 ONCODESIGN SERVICES: COMPANY OVERVIEW 441
LIST OF FIGURES
FIGURE 1 DRUG DISCOVERY SERVICES MARKET SEGMENTATION AND REGIONAL SCOPE 42
FIGURE 2 DRUG DISCOVERY SERVICES MARKET: YEARS CONSIDERED 44
FIGURE 3 DRUG DISCOVERY SERVICES MARKET: RESEARCH DESIGN 46
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT,
DESIGNATION, AND REGION 48
FIGURE 5 GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION, 2024 49
FIGURE 6 COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024 50
FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF
CHARLES RIVER LABORATORIES, 2024 50
FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARIES 52
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 52
FIGURE 10 DRUG DISCOVERY SERVICES MARKET: CAGR PROJECTIONS, 2025–2030 54
FIGURE 11 DRUG DISCOVERY SERVICES MARKET: DATA TRIANGULATION 55
FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2025 VS. 2030 (USD MILLION) 58
FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 59
FIGURE 14 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2025 VS. 2030 (USD MILLION) 59
FIGURE 15 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 60
FIGURE 16 DRUG DISCOVERY SERVICES MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 61
FIGURE 17 REGIONAL SNAPSHOT OF DRUG DISCOVERY SERVICES MARKET, 2025–2030 62
FIGURE 18 INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET 63
FIGURE 19 SMALL MOLECULES SEGMENT AND US LED NORTH AMERICAN DRUG DISCOVERY SERVICES MARKET IN 2024 64
FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 65
FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024 65
FIGURE 22 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66
FIGURE 23 GLOBAL PHARMACEUTICAL R&D SPENDING, 2016–2030 68
FIGURE 24 ACTIVE PHARMACEUTICAL PIPELINE, 2014–2024 69
FIGURE 25 NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS, 2013–2023 70
FIGURE 26 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2013–2023 (USD BILLION) 71
FIGURE 27 NEW REVENUE POCKETS FOR PLAYERS IN DRUG DISCOVERY SERVICES MARKET 80
FIGURE 28 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES,
BY TYPE, 2024 (USD) 81
FIGURE 29 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES,
BY REGION, 2024 (USD) 82
FIGURE 30 DRUG DISCOVERY SERVICES MARKET: SUPPLY CHAIN ANALYSIS 84
FIGURE 31 DRUG DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS 85
FIGURE 32 DRUG DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS 88
FIGURE 33 INVESTMENT AND FUNDING SCENARIO, 2022–2025 91
FIGURE 34 DRUG DISCOVERY SERVICES MARKET: PATENT ANALYSIS, 2014–2024 96
FIGURE 35 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 106
FIGURE 36 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 108
FIGURE 37 KEY BUYING CRITERIA, BY END USER 109
FIGURE 38 AI USE CASES 111
FIGURE 39 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 188
FIGURE 40 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2024) 226
FIGURE 41 DISTRIBUTION OF PHARMACEUTICAL R&D COMPANIES,
BY COUNTRY/REGION, 2023 VS. 2024 231
FIGURE 42 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2024) 268
FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2020−2024 345
FIGURE 44 MARKET SHARE ANALYSIS OF DRUG DISCOVERY SERVICES MARKET, 2024 346
FIGURE 45 RANKING OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2024 347
FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 348
FIGURE 47 EV/EBITDA OF KEY PLAYERS, 2024 348
FIGURE 48 DRUG DISCOVERY SERVICES MARKET: BRAND/SERVICE COMPARISON 349
FIGURE 49 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 352
FIGURE 50 DRUG DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT 353
FIGURE 51 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 360
FIGURE 52 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 368
FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023) 373
FIGURE 54 WUXI APPTEC: COMPANY SNAPSHOT (2023) 379
FIGURE 55 PHARMARON: COMPANY SNAPSHOT (2023) 384
FIGURE 56 LABCORP: COMPANY SNAPSHOT (2023) 390
FIGURE 57 EVOTEC: COMPANY SNAPSHOT (2023) 395
FIGURE 58 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2023) 399
FIGURE 59 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 402
FIGURE 60 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2023) 407
FIGURE 61 GENSCRIPT: COMPANY SNAPSHOT (2023) 411
FIGURE 62 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023) 414
FIGURE 63 PIRAMAL ENTERPRISES LTD.: COMPANY SNAPSHOT (2023) 419
FIGURE 64 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2023) 422
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- コンクリートシーラー市場 – 2030年までの世界予測 2025-04-21
- 自動車用ヒートシールド市場 – 2032年までの世界予測 2025-04-21
- XEVアフターマーケットの進化に関する競争力情報 – 2035年までの世界予測 2025-04-17
- アプリケーションライフサイクル管理市場 – 2029年までの世界予測 2025-04-17
- ヒンダードアミン光安定剤（HALS）市場 – 2030年までの世界予測 2025-04-17